Cancer Therapeutics Overview

Principles

Definition

Cancer therapeutics is a multidisciplinary field of biomedical research and clinical practice focused on the development, evaluation, and application of methods and agents for the treatment of malignant neoplasms. This field investigates diverse strategies aimed at inhibiting tumor growth, eliminating cancer cells, managing disease progression, and improving patient outcomes through pharmacological, surgical, radiological, immunological, and other modalities.

Ontological type

Therapeutic Modalities

Target Identification

Resistance Mechanisms

Key developments

Key Figures

Systemic Chemotherapy Foundations era

Sidney Farber demonstrated that systemic drugs could induce remissions in childhood leukemia in the 1950s using aminopterin, thereby establishing chemotherapy as a cancer treatment paradigm beyond surgery. Louis S. Goodman and Alfred Gilman helped ground this approach by translating nitrogen mustard's activity into a formal chemical and clinical framework, guiding early toxicity assessment and the rationale for combination regimens. Emil J. Freireich and colleagues at the National Cancer Institute pioneered multi-agent, dose-intensive combination chemotherapy for acute leukemia, showing that regimen design and dosing strategies could yield tumor-wide responses. Henry Kaplan and collaborators advanced the era by integrating chemotherapy with radiotherapy and implementing multi-agent regimens for Hodgkin's disease, contributing to the institutionalization of systemic chemotherapy as a standard cancer treatment.

Rational Therapeutics and Standards era

Jaap Verweij [1] is associated with the Institute of Cancer Research [3] and the University of California, San Francisco [4] in this era. His key contributions include shaping standardized response assessment through the New Guidelines to Evaluate the Response to Treatment in Solid Tumors [6], a milestone that enabled reproducible trial comparisons and regulatory benchmarking in the Rational Therapeutics and Standards era. Elizabeth A. Eisenhauer [2] is associated with the Institute of Cancer Research [3] and Johns Hopkins University [5] in this era. Her key contributions include advancing standardized response criteria through the New Guidelines to Evaluate the Response to Treatment in Solid Tumors [6], a legacy that underpinned trial design and regulatory assessment in this era.

Biomarker-Guided Precision Oncology era

Roy S. Herbst [1] is a leading oncologist whose work in the Biomarker-Guided Precision Oncology era spans influential roles at University of California, San Francisco [3] and The University of Texas Southwestern Medical Center [4]. In this era, his contributions include shaping immunotherapy-guided strategies for PD-L1–positive cancers, as evidenced by KEYNOTE-010 [6], which helped validate biomarker-driven patient selection and accelerate the adoption of PD-1–axis therapies. Myung‐Ju Ahn [2] is a prominent researcher affiliated with Harvard University [5] and the University of California, San Francisco [3], contributing to biomarker-guided oncology in this era. Her work, including KEYNOTE-010 [6], highlighted the clinical impact of enrolling PD-L1–expressing patients for pembrolizumab therapy and reinforced the biomarker-centric framework guiding precision oncology in practice.